BEAM - Why Is Apellis Pharmaceuticals Stock Trading Lower Today? | Benzinga
Apellis Pharmaceuticals Inc (NASDAQ: APLS) revealed a comprehensive corporate restructuring plan aimed at catalyzing the growth of its flagship products, Syfovre (pegcetacoplan injection) and Empaveli (pegcetacoplan).
The company is prioritizing the advancement of systemic pegcetacoplan in treating immune complex membranoproliferative glomerulonephritis (IC-MPGN) and C3 glomerulopathy (C3G) - rare kidney disorders.
Top-line data from the Phase 3 VALIANT study are expected in 2024. ...